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Background: Little is known about the healthcare process for patients with prostate cancer, mainly because
hospital-based data are not routinely published. The main objective of this study was to determine the clinical
characteristics of prostate cancer patients, the, diagnostic process and the factors that might influence intervals from
consultation to diagnosis and from diagnosis to treatment.
Methods: We conducted a multicentre, cohort study in seven hospitals in Spain. Patients’ characteristics and
diagnostic and therapeutic variables were obtained from hospital records and patients’ structured interviews from
October 2010 to September 2011. We used a multilevel logistic regression model to examine the association between
patient care intervals and various variables influencing these intervals (age, BMI, educational level, ECOG, first specialist
consultation, tumour stage, PSA, Gleason score, and presence of symptoms) and calculated the odds ratio (OR) and the
interquartile range (IQR). To estimate the random inter-hospital variability, we used the median odds ratio (MOR).
Results: 470 patients with prostate cancer were included. Mean age was 67.8 (SD: 7.6) years and 75.4 % were physically
active. Tumour size was classified as T1 in 41.0 % and as T2 in 40 % of patients, their median Gleason score was 6.0
(IQR:1.0), and 36.1 % had low risk cancer according to the D’Amico classification. The median interval between first
consultation and diagnosis was 89 days (IQR:123.5) with no statistically significant variability between centres. Presence
of symptoms was associated with a significantly longer interval between first consultation and diagnosis than no
symptoms (OR:1.93, 95%CI 1.29–2.89). The median time between diagnosis and first treatment (therapeutic interval)
was 75.0 days (IQR:78.0) and significant variability between centres was found (MOR:2.16, 95%CI 1.45–4.87). This interval
was shorter in patients with a high PSA value (p = 0.012) and a high Gleason score (p = 0.026).
Conclusions: Most incident prostate cancer patients in Spain are diagnosed at an early stage of an adenocarcinoma.
The period to complete the diagnostic process is approximately three months whereas the therapeutic intervals vary
among centres and are shorter for patients with a worse prognosis. The presence of prostatic symptoms, PSA level,
and Gleason score influence all the clinical intervals differently.
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Table 1 List of ethic committees that approval the study
Hospital de la Santa Creu i Sant Pau (Barcelona)
Fundación Puigvert (Barcelona)
Hospital 12 de Octubre (Madrid)
Hospital Ramón y Cajal (Madrid)
Autonómico del País Vasco
Hospital Donosti (San Sebastián)
Hospital General Universitario de Valencia
Hospital Nuestra Señora del Mar (Barcelona)
Hospital Virgen de las Nieves (Granada)
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Prostate cancer is the most frequently diagnosed cancer
among Spanish men. With an incidence of 65.2 per 100
000 persons per year (27 853 new cases yearly 21.7 % of
the total cancer in men), it is overall the second most
frequent cancer in Spain [1]. Worldwide, it is the second
most frequently diagnosed cancer among men (1 111
689 new cases, 15.0 % of all cancers in men) and overall
the fourth most common cancer [1]. The incidence of
prostate cancer has increased over the last decades,
partly due to the more frequent use of diagnostic tools
such as prostate-specific antigen (PSA) testing and nee-
dle biopsies in asymptomatic men [2–4]. The impact on
mortality is high. Mortality rates in Spain showed a
slight increase between 1980 and 1998 but have since
decreased [5, 6]. In 2012, the estimated mortality associ-
ated with prostate cancer was 5481 in Spain and 307
471 worldwide, making it the third leading cause of
death due to cancer for men in Spain (8.6 % of the total)
and the sixth leading cause worldwide (6.6 % of the
total) [1]. Furthermore, prostate cancer reduces the
quality of life of patients [7, 8].
The economic burden of prostate cancer is one of the
largest among malignant tumours due to the high inci-
dence of the disease and increasing survival rates [9]. It
is estimated to cost 11.85 billion USD annually in the
USA [9]. Total costs for diagnosing, treating, and moni-
toring patients with prostate cancer for five years have
been estimated to be approximately £7294.2 per patient
and £92.74 million overall in the United Kingdom [10].
The Spanish Health System is funded by taxes. It of-
fers universal coverage and is managed regionally within
each of the 17 autonomous communities. Healthcare is
divided into two broad areas, primary care and hospital
care. Prostate cancer is generally detected in primary care
centres, where patients might undergo some diagnostic
tests. For confirmatory tests, however, such as a prostate
biopsy, the patient is referred to a hospital for specialised
healthcare. Direct access to specialised healthcare may
also occur through the hospital emergency services, but
this is less frequent.
Several international initiatives have been launched to
obtain detailed and reliable information regarding the
healthcare process for prostate cancer patients. This in-
formation includes the time intervals between first con-
sultation to diagnosis, and first treatment. Such projects
include The European Cancer Registry-based Study of
Survival and Care of Cancer Patients (EUROCARE) [11],
the Patient Outcome Research Teams (PORTS) [12], and
the Cancer of the Prostate Strategic Urologic Research
Endeavour (CAPSURE) [13]. Information can also be ob-
tained from databases containing regional and national
incidence and mortality statistics, from hospital mini-
mum data sets, and from hospital-based cancer registriesthat allow a description and generic comparison of hos-
pital healthcare [14, 15]. These sources of information,
however, do not include the type of data needed to iden-
tify the diagnostic processes, therapeutic approaches,
and prognostic factors in prostate cancer. Recently, one
study regarding prostate cancer has been conducted in
Spain, with the objective to estimate prostate cancer in-
cidence and profile the newly-diagnosed cases using a
nationwide hospital-based registry [16, 17]. However,
this study fails to examine the diagnosis and therapeutic
processes and possible factors influencing these time in-
tervals. The objective of the EMPARO-CU study is to
examine the clinical care process and health outcomes
of patients with urologic tumours during the first year
from the histopathological prostate cancer confirmation.
In this paper we describe the patients’ baseline charac-
teristics at hospital entry and the time intervals between
the first consultation and diagnosis, and between diag-
nosis and start of treatment and possible factors influen-
cing these intervals.
Methods
The EMPARO-CU study is a multicentre, cohort study
of bladder and prostate cancer, conducted in seven
tertiary hospitals in Spain: Fundació Puigvert-Hospital
de la Santa Creu i Sant Pau (coordinating centre) and
Hospital del Mar in Barcelona, Hospital Universitario 12
de Octubre and Hospital Universitario Ramón y Cajal in
Madrid, Hospital Universitario Donostia in Donostia-San
Sebastián, Hospital General Universitario de Valencia in
Valencia, and Hospital Universitario Virgen de las Nieves
in Granada (list of participants in Appendix). The protocol
was approved by the research ethics committees at each
participating centre (Table 1). Patients were enrolled from
October 2010 to September 2011. Consecutive patients
were selected from the urologic and oncology depart-
ments at each centre. Inclusion criteria were: 1) diagnosis
of prostate cancer during the study period, independently
of the tumour stage; 2) diagnosis and treatment at one of
the participating hospitals; and 3) agreement to participate
and signed informed consent.
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process and health outcomes of patients with urologic
tumours. In this paper we describe the patients’ baseline
characteristics at hospital entry and the intervals be-
tween the first consultation and diagnosis, and between
diagnosis and start of treatment. Information regarding
patient status before the diagnosis (such as symptoms at
first visit) was collected retrospectively. Study data were
collected from the medical records and from structured
interviews with individual patients. Variables of interest
were: socio-demographic data, body mass index (BMI),
Charlson index, ECOG WHO score, first specialist con-
sulted, diagnostic tests performed to establish a diagno-
sis of prostate cancer, pathological results of prostate
biopsy [18], PSA values, total Gleason scores, clinical
stages, time from first symptom to first consultation,
and time from first consultation to primary diagnosis
and first treatment (Fig. 1). Time from first symptom to
first consultation was defined as the date on which the
patients experienced the first symptoms related to pros-
tate cancer. The date of first consultation was consid-
ered the date on which the patient first consulted a
healthcare professional for the symptoms that led to
prostate cancer screening. For asymptomatic patients,
the first consultation was considered the date on which
the physician performed prostate screening. We consid-
ered the first histological confirmation as the confirma-
tory diagnosis of the disease. The reference date toFig. 1 Time intervals considered in our studycalculate intervals was the date of biopsy that confirmed
the histological diagnosis of prostate cancer. The time
interval between the first consultation and biopsy was
considered the diagnostic interval. The time between the
biopsy and first treatment was considered the thera-
peutic interval.
Categorical variables are described using relative fre-
quency, and continuous variables are described using
mean and standard deviation (SD) or median and inter-
quartile range (IQR) for skewed distribution variables.
The frequency of missing values is reported for each
variable.
The association between time variables and potential
predictors was assessed using multilevel (patients at first
level and hospitals at second level) logistic regression
models. The variables included as potential predictors in
both models were age, BMI, education level, ECOG
WHO score, specialist at first consultation, primary
tumour clinical stage, PSA value, Gleason score, and
presence of prostate cancer symptoms. Continuous time
variables were transformed into dichotomous variables.
In agreement with previous studies, cut-offs chosen were
an interval of 100 days between first consultation and
diagnosis and 30 days between diagnosis and treatment
[19, 20]. These intervals were based on recommenda-
tions about optimal diagnostic and therapeutic intervals
[21, 22]. We first fitted an empty model that considered
only the random effect of the hospital on the variability
Table 2 Characteristics of prostate cancer patients
Variables N = 470
n (%)
Mean age ± SD 67.8 ± 7.6
Missing (%): 2.3
Mean BMI ± SD 28.1 ± 4.5
Missing (%) 3.8
Working status
Active 83 (17.7)
Sick leave 15 (3.1)
Retired 347 (73.8)
Unemployed 17 (3.6)
Other 4 (0.9)
Missing 4 (0.9)
Education (%)
No education 47 (10.2)
Incomplete primary education 80 (17.2)
Primary education 109 (23.5)
Graduate school 99 (21.3)
Upper secondary studies 62 (13.4)
University 67 (14.5)
Missing 6 (1.2)
Setting first consultation (%)
Primary care 355 (75.5)
Hospital 86 (18.5)
Other 23 (5.0)
Missing 6 (1.2)
Symptoms (%)
No symptoms or discomfort 251 (53.4)
One or more symptoms 170 (36.2)
Missing 49 (10.4)
Start of first symptoms including patients with
discomfort (%)
Since one month 55 (11.7)
Between one month and one year 242 (51.4)
Later than a year 56 (12.0)
No symptoms 68 (14.5)
Missing 49 (10.4)
ECOG WHO (%)
Fully active: 356 (75.7)
Restricted or worse: 105 (22.3)
Missing: 9 (2.0)
Charlson index (%)
1: 358 (75.8)
2: 68 (14.4)
3: 26 (5.5)
Table 2 Characteristics of prostate cancer patients (Continued)
4: 13 (2.8)
≥5: 5 (1.5)
Median PSA (ng/mL) ± IQR 7.6 ± 7.8
Missing (%): 3.4
Total Gleason (%)
2-6: 262 (55.6)
7: 127 (26.9)
>7: 74 (15.6)
Missing: 7 (1.9)
Median total Gleason ± IQR 6.0 ± 1.0
Primary tumour clinical stage (T) (%)
Tx: 1 (0.2)
T1a-c 194 (41.0)
T2a-c: 189 (40.1)
T3a-b : 74 (15.7)
T4: 8 (1.7)
Missing: 4 (1.3)
Regional lymph nodes clinical stage (N) (%)
Nx-N0: 460 (97.7)
N1: 10 (2.3)
Missing: 0 (0.0)
Distance metastasis clinical stage (M) (%)
Mx-M0: 460 (97.9)
M1a-c: 10 (2.1)
Missing: 0 (0.0)
D’Amico Classification (%)
Low risk: 170 (36.1)
Medium risk: 115 (24.5)
High risk: 185 (39.4)
Missing: 0 (0.0)
Median time between first consultation and
diagnosis in days ± IQR
89.0 ± 123.5
Missing (%): 4.0
Median time between diagnosis and first
treatment in days ± IQR
75.0 ± 78.0
Missing (%): 3.2
Median time between first consultation and
first treatment in days ± IQR
176.0 ± 151.0
Missing (%): 6.6
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ate models with each potential predictor. The final model
was fitted through a backward selection procedure based
on Wald tests results. Both the empty model and the final
multilevel models were estimated by maximum likelihood
based on Gaussian quadrature points [23].
Table 3 Diagnostic variables of prostate cancer patients
Diagnostic test N = 470
n (%)
Ultrasound (%)
Prostate ultrasound: 390 (82.9)
Renal ultrasound: 112 (23.8)
Bladder ultrasound: 106 (22.5)
Puncture (%)
Biopsy: 464 (98.7)
Aspiration: 32 (6.8)
Scintigraphy (%) 63 (13.4)
Nuclear magnetic resonance (%)
Abdominal: 66 (14.0)
Thoracic: 1 (0.2)
Cranial: 1 (0.2)
CT scan (%)
Abdominal: 30 (6.4)
Abdominothoracic: 33 (7.0)
Toracic: 14 (3.0)
Cranial: 3 (0.6)
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used the intra-cluster correlation coefficient (ICC) and
the median odds ratio (MOR). The ICC indicates the
fraction of the total outcome variability that is attribut-
able to the area level (in our case, hospital level) and
provides a measure of the within-hospital homogeneity.
A lower ICC indicates a lower likelihood of patients’
sharing hospital experiences. However, because the ICC
can be difficult to interpret because of binary outcomes,
the partition of variance between different levels does
not have the intuitive interpretation of the linear model.
We therefore also calculated the MOR, defined as the
median value of the odds ratio between the hospital at
highest risk (longest time interval) and the hospital at
lowest risk when randomly picking out two hospitals.
The MOR can be conceptualised as the increased risk
(in median) that a patient would have if moved to a hos-
pital with a higher risk [24]. The measure of fixed effect
was the odds ratio (OR) with 95 % confidence intervals.
A p-value lower than 0.05 was considered statistically
significant for all statistical analyses. Data analyses were
performed using SPSS statistical software, version 20.0
(SPSS INC., Chicago, IL, USA) and Stata v12 (StataCorp.
2011. Stata Statistical Software: Release 12. College
Station, TX: StataCorp LP).
Results
Of the 502 patients recruited, 32 were excluded because
they did not meet the inclusion criteria. The study group
was therefore composed of 470 patients. Mean age was
67.8 years (SD:7.6), 337 (71.9 %) had completed at least
primary studies, and 347 (73.8 %) were retired (Table 2).
The mean BMI was 28.1 (SD:4.5) and 354 (75.4 %) had
no physical limitations according to the ECOG WHO
performance status. The Charlson comorbidity index
was between one and three for 451 participants (96.2 %).
Prostate screening was performed in primary care set-
tings for 355 of the 470 patients (75.5 %), and in hospital
settings for 86 of these participants (18.3 %). In 53.4 %
of patients, the disease was identified during a routine
visit or during consultation for another cause because
no symptoms or only discomfort caused by prostate can-
cer had been noted. The median PSA value for the pa-
tients without symptoms was 7.2 (IQR: 6.9). From the
total group, 36.2 % were symptomatic; 48.1 % of these
patients had lower urinary tract symptoms such as in-
creased frequency of urination (16.3 %), and 7.6 % had
symptoms related to the tumour. The time from the first
symptom to first consultation was between one month
and one year for 50.8 % of participants. The clinical
stage of the primary tumour was T1a-c in 41.0 % cases
and T2 a-c in 40 % cases; 2.3 % had regional lymph
nodes (N1) and 2.3 % had distant metastases (M1). The
median PSA value was 7.6 (IQR: 7.8) ng/mL and thetotal Gleason score was between two and six for 55.6 %
of participants. According to the D’Amico classification,
36.1 % of patients had low-risk cancer and 39.4 % had
high-risk cancer (Table 2).
All patients had a prostate biopsy and 82.9 % under-
went a prostate ultrasound study. A renal ultrasonog-
raphy was performed in 23.8 % of patients and a bladder
ultrasonography in 22.5 % (Table 3). Table 4 shows the
patients’ characteristics for each participating hospital.
The median diagnostic interval was 89.0 days (IQR:
123.5). No statistically significant differences were found
between hospitals for this interval (MOR: 1.00). Patients
with one or more symptoms had an OR of 1.93 (95 % CI
1.29–2.89, P = 0.001) of having an interval between first
consultation and diagnosis of more than 100 days
(Table 5). No significant differences were found for
groups of patients differing in age, BMI, education level,
ECOG WHO score, the specialist at first consultation,
primary tumour stage, PSA, or total Gleason scores.
The median therapeutic interval was 75 days (IQR:
78.0) (Table 5). No statistically significant association
was found between groups for this interval regarding
age, BMI, education level, specialist at first consultation,
or primary tumour stage (Table 6). A higher PSA value
and a higher Gleason score shortened the interval be-
tween diagnosis and treatment. Patients with a PSA
value higher than 10 or a total Gleason score higher
than 7 had an OR of 0.5 (95 % CI 0.29–0.86, P = 0.012)
and 0.53 (95 % CI 0.30–0.93, P = 0.026), respectively, to
Table 4 Characteristics of prostate cancer patients by hospitals
Centres A (n = 48) B (n = 91) C (n = 37) D (n = 78) E (n = 112) F (n = 33) G (n = 75)
Mean age ± SD 72.6 ± 6.1 66.9 ± 7.7 67.3 ± 5.6 67.8 ± 6.7 67.1 ± 7.8 66.2 ± 6.9 67.6 ± 9.2
Missing (%): 0.0 2.2 0.0 5.1 0.0 6.1 4.1
Mean BMI ± SD 28.2 ± 5.7 27.3 ± 3.5 27.6 ± 3.8 28.8 ± 6.4 28.9 ± 4.1 27.6 ± 4.3 27.2 ± 2.9
Missing (%): 0.0 4.4 0.0 3.8 0.9 21.2 4.1
Median PSA (ng/mL) ± IQR 10.4 ± 15.5 5.7 ± 3.4 6.7 ± 3.7 7.8 ± 7.7 8.6 ± 12.2 7.0 ± 3.8 8.7 ± 8.2
Missing (%): 2.1 8.8 0.0 6.4 0.0 3.0 1.4
ECOG WHO (%)
Fully active: 72.9 84.6 91.9 71.8 69.6 63.6 75.3
Restricted or worse: 25.0 15.4 8.1 23.1 30.4 33.3 17.8
Missing: 2.1 0.0 0.0 5.1 0.0 3.0 6.8
Primary tumour clinical stage (T) (%)
Tx: 0.0 0.0 0.0 1.3 1.3 0.0 0.0
T1a-c 45.8 45.1 16.2 37.2 37.2 43.8 41.1
T2a-c: 43.8 39.6 56.8 37.2 37.2 33.0 19.3
T3a-b : 6.3 14.3 21.6 20.5 20.5 22.3 6.8
T4: 4.1 1.0 0.0 3.8 3.8 0.9 1.4
Missing: 0.0 0.0 5.4 0.0 0.0 0.0 1.4
Regional lymph nodes clinical stage (N) (%)
Nx-N0: 100.0 98.9 100.0 92.3 100.0 100.0 97.3
N1: 0.0 1.1 0.0 7.7 0.0 0.0 2.7
Missing: 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Distance metastasis clinical stage (M) (%)
Mx-M0: 95.8 100.0 100.0 93.6 98.2 100.0 98.6
M1a-c: 4.2 0.0 0.0 6.4 1.8 0.0 1.4
Missing: 0.0 0.0 0.0 0.0 0.0 0.0 0.0
D’Amico Classification (%)
Low risk: 14.6 50.5 54.1 32.1 39.3 36.4 21.9
Medium risk: 27.1 12.1 29.7 17.9 23.2 45.5 34.2
High risk: 58.3 37.4 16.2 50.0 37.5 18.1 42.5
Missing: 0.0 0.0 0.0 0.0 0.0 0.0 1.4
Total Gleason (%)
2-6: 16.7 73.6 64.9 68.0 66.9 36.4 31.5
7: 29.2 19.8 29.7 17.9 18.8 51.5 43.8
>7: 54.1 6.6 2.7 10.2 14.3 9.1 19.2
Missing: 0.0 0.0 2.7 3.9 0.0 3.0 5.5
Median total Gleason ± IQR 8.0 ± 1.0 6.0 ± 1.0 6.0 ± 1.0 6.0 ± 2.0 6.0 ± 1.0 7.0 ± 1.0 7.0 ± 1.0
Median time between first consultation
and diagnosis in days ± IQR
99.5 ± 139.0 79.0 ± 211.0 110.0 ± 117.0 78.5 ± 107.3 92.0 ± 99.0 133.0 ± 195.0 76.5 ± 100.0
Missing (%): 0.0 3.3 5.4 7.7 4.5 6.1 1.4
Median time between diagnosis and
first treatment in days ± IQR
30.5 ± 127.5 78.0 ± 62.0 83.0 ± 72.0 104.0 ± 70.5 55.0 ± 66.5 73.5 ± 84.5 70.0 ± 95.0
Missing (%): 0.0 4.4 0.0 1.3 6.3 3.0 2.7
Median time between first consultation
and first treatment in days ± IQR
164.0 ± 232.0 154.0 ± 207.0 212.0 ± 165.0 200.0 ± 130.0 166.0 ± 112.8 203.0 ± 149.8 165.0 ± 128.5
Missing (%): 0.0 6.6 5.4 9.0 8.9 9.1 4.1
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Table 5 Time interval between first consultancy and diagnosis and potential determinant (Univariate regression)
ICC/MOR 95 % CI MOR P-value
Hospital random effect 0.00
Empty model 1.00 1.00–1.00 1.000
Median (days) IQR (days) OR >100 days 95 % CI OR
Age
<65 years 84.0 182.0 1
≥65 years 91.0 105.5 0.96 0.64–1.43 0.830
BMI
<25 102.0 163.0 1
≥25 86.0 110.3 0.64 0.40–1.01 0.057
Education level
Primary education or lower 90.5 108.5 1
Graduate school or higher 86.0 139.0 1.00 0.69–1.45 0.992
ECOG WHO Score
Fully active 87.5 126.8 1
Restrictive or worse 95.0 129.0 1.18 0.76–1.83 0.474
Specialist first consultation
Primary care 91.0 139.5 1
Hospital or specialist 79.0 106.0 0.78 0.50–1.22 0.277
Primary tumour clinical stage (T)
T1a–T1c 95.5 141.3 1
T2a–T4 85.0 108.5 0.73 0.50–1.07 0.110
PSA value
<10 95.0 135.5 1
≥10 84.0 108.5 0.81 0.54–1.21 0.310
Total Gleason score
<7 87.0 140.0 1
≥7 91.0 111.5 0.87 0.60–1.27 0.464
Symptoms
No symptoms or discomfort 83.0 110.0 1
One or more symptoms 110.0 174.0 1.93 1.29–2.89 0.001
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more than 30 days. The MOR for the random effect of
the hospital where the patient received care was 2.16
(95 % CI 1.45–4.87, P = 0.000).
Discussion
This multicentre cohort study aimed to describe the
healthcare process in patients with prostate cancer in
Spain. We focused on the characteristics of patients and
tumours and we evaluated diagnosis and treatment de-
lays in healthcare.
Our study included 470 patients diagnosed with
prostate adenocarcinoma in a hospital care setting.
Prostate biopsy and ultrasound were the most fre-
quently performed diagnostic tests. The mean age ofour population, the proportion of asymptomatic low
risk patients and the median Gleason grade were
similar to those reported in previous studies in Spain
and in other countries [16, 19, 25–29]. The percent-
age of localised tumours in our population (81 %)
was similar to that in an earlier study (89.8 %) in
Spain conducted by Cozar et al. but considerably
higher than that in the European study of Gatta et al.
These discordant findings might be explained by dif-
ferences between countries and years regarding acces-
sibility to health services and physicians’ attitudes
towards screening tests [30].
In our study, clinical symptoms were present in 36.2 %
of all patients, the most common symptom being disor-
ders of the lower urinary tract (48.1 %) and symptoms
Table 6 Time interval between diagnosis and first treatment and potential determinants
Characteristic Univariate regression Multivariate regression
Hospital random effect Empty model
ICC/MOR
95 % CI
MOR
P-value FInal model
ICC/MOR
95 % CI
MOR
P-value
0.18/2.22 1.52–4.58 0.000 0.17/2.16 1.45–4.87 0.000
Median (days) IQR (days) OR >30 days 95 % CI OR OR >30 days 95 % CI OR
Age
<65 years 78.0 74.0 1
≥65 years 71.0 79.0 0.70 0.40–1.21 0.198
BMI
<25 75.0 76.0 1
≥25 72.0 81.0 1.06 0.60–1.90 0.831
Education level
Primary education or lower 76.0 77.8 1
Graduate school or higher 70.0 77.5 1.25 0.76–2.06 0.386
ECOG WHO Score
Fully active 77.0 74.8 1
Restrictive or worse 54.0 77.0 0.55 0.32–0.95 0.033
Specialist first consultation
Primary care 76.0 77.0 1
Hospital or specialist 74.0 79.5 0.86 0.48–1.56 0.621
Primary tumour clinical stage (T)
T1a–T1c 84.0 77.0 1
T2a–T4 69.0 79.0 0.59 0.35–0.98 0.040
PSA value
<10 86.0 75.0 1
≥10 50.0 81.0 0.41 0.24–0.68 0.001 0.50 0.29–0.86 0.012
Gleason score
<7 85.5 68.8 1
≥7 55.0 88.0 0.42 0.25–0.71 0.001 0.53 0.30–0.93 0.026
Symptoms
No symptoms or discomfort 78.0 72.0 1
One or more symptoms 73.5 80.3 0.62 0.37–1.05 0.073
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to those in the study of Cozar et al. where the frequency
of lower urinary tract symptoms was 39.5 % of patients
and the frequency of symptoms related to the tumour
was 11.6 % [16]. In our study, the median interval be-
tween first consultation and diagnosis was 89.0 days,
comparable to the 72 days in the study by Hansen et al.
[31] and the 101 days reported by Torring et al. [32].
We did not find any variability in diagnostic interval
between hospitals regarding age, BMI, education level,
first visit with a specialist, tumour stage, PSA value, or
Gleason score. However, the presence of symptoms
lengthened this interval possibly because some symp-
toms of prostate cancer can be confused with benign
prostatic hyperplasia.Previous studies in Spain that determined the thera-
peutic intervals in cancer patients were generally con-
ducted in a single hospital [33–35]. The most recently
published multicentre study analysed this interval for six
types of cancer, including prostate cancer [19], and
found the mean therapeutic interval was longer than in
our study (102.5 days (SD:71.6) vs. 80.4 days (SD:60.9)).
However, we defined this interval as the time between
the biopsy and the first oncological treatment, whereas
the investigators in the previous study defined it as the
time between the first diagnostic test of any kind and
first oncological treatment. In contrast with the study by
Perez et al. [19], our study was prospective, it had a lar-
ger number of cases, patients were from several different
autonomous regions of the country, and information
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through patient interviews.
We observed that patients with a higher PSA value
and a higher Gleason score had a shorter interval be-
tween diagnosis and first treatment than patients with
lower values. Pérez et al. [19] reported similar findings
in patients with advanced stages of prostate cancer. An
explanation for this shorter interval could be that due to
their worse prognosis, these patients usually receive hor-
monal therapy initially or exclusively, a treatment that is
easier to administer than radiotherapy, chemotherapy, or
surgery [36].
Our results show a statistically significant variability
between centres in relation to the therapeutic interval.
The heterogeneity in intervals could be associated with
the wide diversity in population characteristics, health-
care organisation and clinical policies in the different re-
gions in Spain.
One of the main strengths of our study is that our
sample of patients is a representative sample of the ap-
proximately 28.000 yearly incident prostatic cancer pa-
tients diagnosed in Spain because they were recruited
from seven hospitals in five autonomous regions. In
addition, the study’s prospective nature guarantees
consistency and accuracy of the data collected, surpass-
ing the common shortcomings of a retrospective collec-
tion of information. The study may have limitations,
however, such as information bias. Given that it is based
exclusively on information obtained in a hospital setting,
outpatient factors such as those related to consultation
at a primary level, could not have been taken into con-
sideration. Nevertheless, as urologic cancer care is
mainly provided in the hospital setting, in our view this
limitation has little practical relevance.
Conclusions
Most incident prostate cancer patients in Spain are diag-
nosed at an early stage of an adenocarcinoma. The
period to complete the diagnostic process is approxi-
mately three months whereas the therapeutic intervals
vary among centres and are shorter for patients with a
worse prognosis. The presence of prostatic symptoms,
PSA level, and Gleason score influence the clinical inter-
vals differently.
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